Calling AbbVie Inc. (NYSE:
ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said:
“Or how about one of my absolute favorites right here too, AbbVie. Now here's a drug company with no patent cliff in sight whatsoever. Got tremendous franchises in neurology, oncology, immunology, and medical aesthetics, among others. Because of today's vicious bond market-inspired selloff, this fine stock's down a quick 10 points today or more than 5%, but it only yields 3.7%. With rates going higher, you have to wonder if AbbVie's worth the risk, even as it's among the safest, if not the safest stock in the group, because of these amazing franchises.
I think it makes a ton of sense to start a position in the stock right now, if only because of the amazing Skyrizi and Rinvoq immunology drugs, as well as BOTOX, which right now is sainted for those who get too many wrinkles as their skin sags from taking GLP-1s, those are the drugs that combat obesity and diabetes. I don't know, tempting.”
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
AbbVie Inc. (NYSE:ABBV) is a drug company that works on discovering, producing, and selling a wide variety of medicines.
While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this
cheapest AI stock.
READ NEXT: Jim Cramer Put These 8 Stocks Under a Microscope Recently and Jim Cramer Commented on These 6 Natural Gas Players
Disclosure: None.
